Knockdown of SLC7A11 in tumor cells, overexpression of SLC7A11 in T cells, overexpression of GCLC in T cells, and cystine supplementation enhanced the anti-tumor ability of CD8+ T cells (65). This evidence concerns the gene SLC7A11 and neoplasm.